ArticleUltrasonography (Seoul, Korea)2026
Diagnostic performance of ultrasound-derived fat fraction for assessing steatotic liver disease with histopathology as the reference.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasound-based fat quantification: advancing steatosis assessment in the metabolic dysfunction-associated steatotic liver disease era.Ultrasonography (Seoul, Korea) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeThis study was performed to evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) for detecting hepatic steatosis in patients with steatotic liver disease (SLD), using liver biopsy and histopathology as the gold standard.
methodsIn this prospective study, patients referred for evaluation of suspected SLD were enrolled. All patients underwent UDFF and controlled attenuation parameter (CAP) measurements. Histopathological findings were assessed using the steatosis-activity-fibrosis scoring system as the gold standard. Pearson or Spearman correlation analyses and multivariate linear regression were performed. Areas under the receiver operating characteristic curves (AUCs) were utilized to assess the diagnostic performance of UDFF and CAP in identifying hepatic steatosis. The DeLong test was used to compare AUCs.
resultsFrom February 2023 to May 2025, 66 patients were included. The median body mass index was 24 kg/m2. UDFF was positively correlated with hepatic steatosis grade (r=0.66). Using UDFF thresholds of 9.5%, 14.5%, and 16.3% (determined by the Youden index), the AUCs for detecting steatosis grades ≥S1, ≥S2, and S3 were 0.82, 0.90, and 0.99, respectively. UDFF exhibited a significantly higher AUC than CAP for detecting steatosis grade S3 (P=0.037). UDFF was correlated with hepatic steatosis grade, activity grade, CAP, aspartate aminotransferase level, and albumin level (all P<0.05).
conclusionUDFF demonstrated good diagnostic performance for assessing hepatic steatosis, using histopathology as the reference. UDFF may serve as a quantitative imaging approach to measure liver fat content in patients with SLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.